Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories


Prenetics tests out $1.25bn reverse merger
Genetic testing services provider Prenetics, a spinout of City University of Hong Kong, will hold a reverse merger at a $1.25bn valuation.
Context Therapeutics frames IPO plans
Based on research at Drexel University, Context Therapeutics is seeking to raise up to $21m in an initial public offering on Nasdaq.
Exscientia explores Nasdaq IPO
Dundee spinout Exscientia is continuing a busy fundraising year with a filing for an IPO in the US and a $35m concurrent private placement.
Icosavax lands on $182m IPO
UW's vaccine development company has listed on Nasdaq, with its shares rising on the first day of trading.
Tenaya tends to $180m IPO
The GV-backed cardiovascular therapeutics company has priced an upsized offering on Nasdaq, with the shares closing just marginally higher on the first day.
Duolingo brings in $521m IPO
Carnegie Mellon-linked Duolingo raised $521m in an upsized offering and saw its shares rise 36% on their first day.
Sema4 secures Nasdaq listing
Icahn School of Medicine spinout Sema4 has completed a reverse merger with CM Life Sciences to begin trading on the Nasdaq Global Select Market.
Caribou Biosciences careers on to public markets
UC Berkeley’s cancer therapy developer priced a $304m initial public offering at the top of its range.

Other News

IsoPlexis applies itself to IPO filing
Yale University is in line to exit proteomics platform developer IsoPlexis in a Nasdaq Global Market offering with a $100m placeholder target.
Kin to clinch public markets spot
The UChicago-backed digital home insurance provider is joining forces with Omnichannel Acquisition Corp at a valuation of just over $1bn.
TScan takes in $100m through IPO
Harvard spinout TScan Therapeutics has successfully listed on the Nasdaq Global Market.
Dynacure sets sights on $107m IPO
The IGBMC spinout was set up by Satt Conectus and is now seeking a listing in the US with a price range of $15 to $17.
Tenaya Therapeutics tenses for IPO
Th heart disease treatment developer has secured $248m in funding since being formed to exploit UT Southwestern and Gladstone Institute research.
Icosavax initiates IPO procedure
University of Washington spinout Icosavax has filed for an initial public offering on the Nasdaq Global Select Market, with financial terms yet to be set.

Editor's Picks

Aerovate accesses public markets
Less than a year after raising $72.6m in its series A round, Aerovate Therapeutics has gone public following an IPO worth more than $121m.
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg